LitAlert ~~ GeneLit.com

    • Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    • Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
    • Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.

    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.

    • Common germline risk variants impact somatic alterations and clinical features across cancers.
    • Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
    • Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.

    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.